Nyrekreft, nyrecellekreft

Dette dokumentet er basert på det profesjonelle dokumentet Nyrekreft. Referanselisten for dette dokumentet vises nedenfor.

1. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med nyrecellekreft. Helsedirektoratet 2015.
2. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2019 May;30(5):706-20. PMID: 30788497 PubMed 
3. Amin MB, Edge S, Green F, et al. AJCC cancer staging manual. 8th ed. (2017). Cham, Switzerland: Springer International; 2017.
4. Kreftregisteret. Cancer in Norway 2021. Oslo: Kreftregisteret, 2022, www.kreftregisteret.no. www.kreftregisteret.no 
5. Motzer RJ, et al. Kidney cancer, version 2. 2017. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(6):804–834.
6. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) program. Cancer stat facts: kidney and renal pelvis cancer. 2020 seer.cancer.gov 
7. Maher ER. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol. 2018; 36:1891-8. PMID: 29680948 PubMed 
8. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004. PubMed 
9. Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 2014;21(1):81–90.
10. Peyromaure M, Misrai V, Thiounn N, et al. Chromophobe renal cell carcinoma: analysis of 61 cases. Cancer 2004; 100: 1406-10. PubMed 
11. Cumberbatch MG, Rota M, Catto JW, La Vecchia C . The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks.. Eur Urol 2016; 70: 458. pmid:26149669 PubMed 
12. Capitano U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol 2019; 75: 74-84. pmid:30243799 PubMed 
13. Alanee S, Clemons J, Zahnd W, Sadowski D, Dynda D. Trichloroethylene is associated with kidney cancer mortality: a population-based analysis. Anticancer Res. 2015;35(7):4009–4013. PMID: 26124349. PubMed 
14. Kompotiatis P, Thongprayoon C, Manohar S, et al. Association between urologic malignancies and end-stage renal disease: A meta-analysis. Nephrology (Carlton). 2019; 24: 65-73. PMID: 29236344 PubMed 
15. Loo RK, Lieberman SF, Slezak JM, et al. Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin Proc. 2013;88(2):129–138.
16. Gray RE, Harris GT. Renal cell carcinoma: diagnosis and management. Am Fam Physician. 2019 Feb 1;99(3):179-184. PubMed 
17. Campbell S, Uzzo RG, Allaf ME, et al. Renal mass and localized renal cancer: AUA guideline. J Urol. 2017 Sep;198(3):520-9. PMID: 28479239 PubMed 
18. Ouzaid I, Capitanio U, Staehler M, et al. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol. 2019 Mar;2(2):141-9. PMID: 31017089 PubMed 
19. Powles T, Albiges L, Bex A et al.: ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021 Dec;32(12):1511-1519. Epub 2021 Sep 28. PMID: 34597799.
20. Powles T; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Mar;32(3):422-423. Epub 2020 Nov 30. PMID: 33271289.
21. Pessoa RR, Kim S. Renal cell carcinoma. BMJ Best Practice, last reviewed Aug 2022. bestpractice.bmj.com